MARKET

COGT

COGT

Cogent Biosciences Inc
NASDAQ
39.31
+0.15
+0.38%
After Hours: 39.31 0 0.00% 17:42 12/04 EST
OPEN
39.16
PREV CLOSE
39.16
HIGH
39.58
LOW
37.94
VOLUME
2.47M
TURNOVER
--
52 WEEK HIGH
41.27
52 WEEK LOW
3.720
MARKET CAP
6.30B
P/E (TTM)
-22.2530
1D
5D
1M
3M
1Y
5Y
1D
3 Potential Mid-Cap Biotech Buyout Targets In 2026
Seeking Alpha · 1d ago
Weekly Report: what happened at COGT last week (1124-1128)?
Weekly Report · 3d ago
A Look at Cogent Biosciences (COGT) Valuation Following Positive Phase 3 Trial Results
Simply Wall St · 11/28 00:22
Why Cogent Biosciences (COGT) Is Up 18.9% After Positive Phase 3 GIST Trial Results
Simply Wall St · 11/26 07:25
Weekly Report: what happened at COGT last week (1117-1121)?
Weekly Report · 11/24 09:31
U.S. RESEARCH ROUNDUP-Alignment Healthcare, BJ's Wholesale Club Holdings, Hyatt Hotels
Reuters · 11/24 08:05
COGENT BIOSCIENCES INC <COGT.O>: PIPER SANDLER CUTS TARGET PRICE TO $39 FROM $40
Reuters · 11/24 03:49
A Look at Cogent Biosciences’s Valuation After Positive Phase 3 Data and Major Funding Updates
Simply Wall St · 11/19 12:32
More
About COGT
Cogent Biosciences, Inc. is a biotechnology company. The Company is focused on developing precision therapies for genetically defined diseases. The Company’s clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3Kα. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.

Webull offers Cogent Biosciences Inc stock information, including NASDAQ: COGT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, COGT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading COGT stock methods without spending real money on the virtual paper trading platform.